I lllll llllllll Ill lllll lllll lllll lllll lllll 111111111111111111111111111111111
`
`US007892549B2
`
`c12) United States Patent
`Paton et al.
`
`(IO) Patent No.:
`(45) Date of Patent:
`
`us 7,892,549 82
`*Feb.22, 2011
`
`(54) TREATMENT WITH ANTl-ERBB2
`ANTIBODIES
`
`(75)
`
`Inventors: Virginia E . Paton, Oakland, CA (US);
`Steven Shak, Bur lingame, CA (VS);
`Su san D. Hellman n, San Carlos, CA
`(US)
`
`(73) Assignee: G enentech , Inc., South San Francisco,
`CA (US)
`
`( *) Notice:
`
`Subject to any djsclaimer, the term of tills
`patent is extended or adjusted under 35
`U.S.C. 154(b) by 1827 days.
`
`This patent is subject to a tenninal dis(cid:173)
`claimer.
`
`(21) Appl. No.: 10/356,824
`
`(22) Filed:
`
`Feb. 3,2003
`
`(65)
`
`P rior P ublication Data
`
`US 2004/0037823 A9
`
`Feb.26, 2004
`
`Related U.S. Application Data
`
`(63) Continuation of application No. 09/208,649, filed on
`Dec. 10, 1998.
`(60) Provisional application No. 60/069,346, filed on Dec.
`12, 1997.
`
`(51)
`
`Int. C l.
`A61K 391395
`(2006.01)
`C07K 16128
`(2006.01)
`C07K 16130
`(2006.01)
`(52) U.S. Cl. .............. 424/143.1; 424/130.l ; 4241133.l ;
`424/ 134.J; 424/135.1 ; 4241136.1; 424/ 138.1:
`424/ l 4J. I ; 424/152.1 ; 424/155.1 ; 424/ I 56.I ;
`4241172.l: 424/174.l
`(58) F ield of C lassification Search .............. 424/ 130.1.
`424/133.J , 138.1. 141.1 , 143.1, 155.1. 174.1,
`424/ 134. l , 135.1, 136.1. 152. l , 156.1 , 172.I
`See application file for complete search history.
`
`5.578,482 A
`5.587,458 A
`5,604,107 A
`5,641,869 A
`5,663,144 A
`5,677,171 A
`5,705,157 A
`5,720,937 A
`5,720,954 A
`5,725,856 A
`5.726,023 A
`5,728,687 A
`5.747,261 A
`5,770,195 A
`5.772,997 A
`5,776,427 A
`5.783,186 A
`5,783,404 A
`5,801,005 A
`5,804,396 A
`5,821,337 A
`5.824,311 A
`5,834,229 A
`5.837,243 A
`5,837,523 A
`5,840,525 A
`5,846,538 A
`
`1111996 Lippman el al.
`1211996 Ki ng et al.
`211997 Carney el al.
`6/ 1997 Vandlcn ct al.
`9/ 1997 Greene ct al .
`1011997 Hudziak ct al.
`1/ 1998 Greene
`211998 Hudziak et al.
`211998 Hudziak et al.
`3/1998 Hudziak el al.
`3/ 1998 Cheever e1 al.
`3/ 1998 Bissery
`511998 King et al
`6/ 1998 Hudziak et al.
`611998 Hudziak et al.
`7/ 1998 Thorpe el al.
`7/ 1998 Arakawa et al.
`7/ 1998 Koski
`9/ 1998 Cheever el al.
`9/ 1998 Plowman
`10/ 1998 Carter et al.
`10/ 1998 Greene et al.
`1111998 Vandlen ct al.
`11/ 1998 Deoel al.
`11/ 1998 Greene et al.
`I 1/ 1998 Vandlen el al.
`1211998 Cheever et al.
`
`(Continued)
`
`FOREIGN PATENT DOCUMENTS
`
`EP
`
`0599274 A l
`
`6/ 1994
`
`(Continued)
`
`OTHER PUBLICATJONS
`
`Kim. K.-M. et al, Int. .I. Cancer, 102: 428-434, 2002.•
`
`(56)
`
`Refer ences C ited
`
`(Continued)
`
`U .S. PATENT DOCUMENTS
`
`4,017.47 1 A
`4,753,894 /\
`4,935.34 1 A
`4,943.533 A
`4,968,603 A
`4,975,278 A
`4,994,558 A
`5,169,774 A
`5,183,884 A
`5,288,477 A
`5.359.046 A
`5,367,060 A
`5,401,638 A
`5,464.75 1 A
`5,480,968 A
`5.5 14.554 A
`5,571,894 A
`
`4/ 1977 Davies
`6/ 1988 Frankel ct al.
`6/ 1990 Bargmann el al.
`7/ 1990 Mendelsohn et al.
`J II 1990 Slamonetal.
`1211990 Senter ct al.
`211991 Armour et al.
`1211992 Frankel et al.
`2/ 1993 Kraus el al.
`21 1994 Bacus
`1011994 Capon et al.
`11/ 1994 Vandlen et al.
`3/ 1995 Carney et al.
`11/ 1995 Greene el al.
`1/ 1996 Kraus et al.
`511996 Bacus
`11/ 1996 Weis ct al.
`
`Primary Examiner- Alana M. Harris
`Assistant Examiner- Anne L Holleran
`(74) A1torney, Age111, or Firm- Arnold & Poiter LLP; Diane
`Marschang; Ginger R. Dreger
`
`(57)
`
`ABSTRACT
`
`T he present invention concerns the treatment of disorders
`characterized by the overexpression ofErb82. More specifi(cid:173)
`cally. the invention concerns the treatment of human patients
`susceptible to or diagnosed with cancer overexpressing
`ErbB2 with a combination of an anti-ErbB2 antibody and a
`chemotherapeutic agent other than an anthracyc]ine, e.g.
`doxo rubicin or epirubicin.
`
`17 C la ims, l Dr awing Sheet
`
`1 of 24
`
`Celltrion, Inc., Exhibit 1001
`
`

`

`U.S. PATENT DOCUMENTS
`
`5,846,749 A
`5,856.089 A
`5,856.1 10 A
`5,859,206 A
`5,869,445 A
`5,876,7 12 A
`5,877,305 A
`5,908.835 A
`5,9 10,486 A
`5,922,845 A
`5.925.5 19 A
`5,939,53 1 A
`5,977.322 A
`5,985,553 A
`5,994,071 A
`6,0 15.567 A
`6.028,059 A
`6,054,297 A
`6,054.56 1 A
`6.123.939 A
`6,165,464 A
`6,2 14.388 B l
`6.2 14.863 BJ
`6,267.958 B J
`6,270.765 B I
`6.3 16.462 Bl
`6,333.348 Bl
`6,339.142 B l
`6.387.371 B l
`6,395.272 Bl
`6.395.7 12 Bl
`6.399,063 Bl
`6,407,213 Bl
`6,458,356 B I
`6,5 12,097 B J
`6,627.196 Bl
`6,639,055 B l
`6.685,940 B2
`6,7 19,971 Bl
`6,800,738 Bl
`6,82 1,5 15 Bl
`7,04 1,292 Bl
`7,060,268 B2
`7,097,840 B2
`200l/00 14326 A l
`2002/0001587 A 1
`200210076408 A 1
`200210155527 Al
`2003/0 l 03973 Al
`2003/0 l 08545 A l
`2003/0147884 A l
`2003/0170234 Al
`2003/0202972 A l
`2004/00 13660 A 1
`2004/0037823 A9
`2004/0037824 A I
`2004/0106161 A l
`2004/0236078 Al
`2004/0258685 Al
`2005/0002928 A l
`2005/0208043 A l
`2005/0238640 A l
`2005/02444 17 A l
`2006/0013819 Al
`2006/00 18899 Al
`2006/0034840 A I
`2006/0034842 Al
`2006/0073143 A I
`2006/0083739 A I
`2006/0088523 Al
`2006/0099201 Al
`
`12/ 1998 Slamon eta!.
`1/ 1999 Wang et al.
`1/ 1999 Vandlen el al.
`1/ 1999 Vandkn et al.
`211999 Cheever et al.
`3fl999 Cheever et al.
`311999 Huston et al.
`6/ 1999 Bisscry
`611999 Curiel el al.
`7/1999 Deo etal.
`711999 Jensen et al.
`811999 Weis et al.
`l l/ 1999 Marks ct al.
`ll/1999 King etal.
`J 1/ 1999 Ross el al.
`1/2000 Hudziak el al.
`2/2000 Curiel et al.
`4/2000 Carter el al.
`4/2000 Ring
`9/2000 Shawver el al.
`1212000 Hudziak et al.
`4/200 1 Benz etal.
`4/2001 Bissery
`7/200 1 Andya eta!.
`81200 1 Deoclal.
`ll/2001 Bishop et al.
`121200 1 Vogel et al.
`1/2002 Basey et al.
`5/2002 Hudziak et al.
`512002 Dcoctal.
`512002 Hung cl al .
`6/2002 Hudziak el al.
`612002 Carter Cl al.
`1012002 Arakawa et al.
`J/2003 Marks et al.
`9/2003 Baughman et al.
`10/2003 Carter el al.
`2/2004 Andya eta!.
`4/2004 Carter el al.
`10/2004 Carter et al.
`I 1/2004 Cleland et al.
`512006 Sliwkowski
`612006 Andyaet al.
`8/2006 Erickson et al.
`81200 l Andyaet al.
`1/2002 Erickson et al.
`6/2002 Buchsbaum
`1012002 Stuart ct al.
`6/2003 Rockwell et al.
`6/2003 Rockwell et al.
`812003 Paton et al.
`9/ 2003 Hellmann
`10/2003 Andyaetal.
`1/2004 Bissery
`212004 Paton et al.
`212004 Baughman et al.
`6/2004 Bosserunaier et al.
`11/2004 Carter et al.
`12/2004 Brunett a et al.
`1/2005 Hellmann
`9/ 2005 Adams ct al.
`10/2005 Sliwkowski
`1112005 Ashkenazi et al.
`1/2006 Kelsey
`1/2006 Kao ct al.
`212006 Agus
`212006 Adams et al.
`4/2006 Adams et al.
`4/2006 Sliwkowski
`4/2006 Andyaetal.
`5/2006 Andya etal.
`
`US 7,892,549 B2
`Page2
`
`2006/012 1044 Al
`2006/0165702 A J
`2006/0188509 A l
`200610193854 Al
`200610198843 A J
`2006/0204505 A l
`200610210561 Al
`2006/0228745 A l
`2006/0275305 A l
`2006/0275306 Al
`2007/002026 1 A l
`2007/0026001 A l
`2007/0037228 Al
`2007/0166753 A l
`2007/0184055 Al
`2007/0202516 A l
`2007/0224203 A l
`2007/0269429 A l
`2007/02924 19 A l
`
`612006 Amler et al.
`7/2006 Allison et al.
`8/2006 Deryock et al.
`812006 Adams et al.
`9/2006 Adams et al.
`9/2006 Sliwkowski et al.
`9/2006 Baughman ct al.
`10/2006 Mass
`1212006 Bryant
`12/2006 Andya etal.
`1/2007 Sliwkowski et al.
`212007 Ashkenazi et al.
`2/2007 Moecks el al.
`7/2007 Mass
`8/2007 Sliwkowski
`812007 Mass
`9/2007 Friess et al.
`11/2007 Kelsey et al.
`1212007 Hellmann
`
`FOREIGN PATENT DOCUMENTS
`
`EP
`EP
`JP
`JP
`JP
`JP
`JP
`JP
`JP
`JP
`JP
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`
`616812 Al
`071 1565 Bl
`3-240498
`5-1 17 165
`5-170667
`5-213775
`5-317084
`95006982 B2
`7-59588
`2761543 B2
`2895105 B2
`WO 87/07646
`WO 89/06692
`WO 89/ 104 12
`W091/02062
`W09J/05264
`W092110573
`W093/03741
`W093/ 12220
`W093/ 16185
`W093/21232
`W093/21319
`W094/00136
`W094/22478
`W094/28 127
`W095/ 16051
`W095/17507
`W095/28485
`W096/07321
`W096/l6673
`W096/l8409
`W096/40789
`W097/00271
`W097/20858
`W097/27848
`W097/38731
`W098/02463
`W098/l7797
`W098/18489
`WO 981339 14
`W098/45479
`W099/24401
`W099/25320
`W099/31140
`WO 00/61145
`WO 00/611 85
`WO 00169460 A I
`WOOl/87334
`WO 02/055 106
`
`911 994
`8/1998
`10/1991
`5/1993
`7/ 1993
`811993
`12/ 1993
`1/ 1995
`311995
`6/ 1998
`5/ 1999
`12/ 1987
`7/ 1989
`1111989
`2/ 1991
`4/1991
`6/ 1992
`3/ 1993
`6/ 1993
`811993
`10/ 1993
`10/ 1993
`l/ 1994
`10/1994
`1211994
`6/ 1995
`611995
`10/1995
`3/1996
`6/1996
`611996
`12/ 1996
`1/ 1997
`6/ 1997
`8/1997
`10/1997
`111998
`4/1998
`5/ 1998
`811998
`10/ 1998
`5/ 1999
`511999
`6/ 1999
`10/2000
`10/2000
`l l/2000
`ll/2001
`7/2002
`
`2 of 24
`
`Celltrion, Inc., Exhibit 1001
`
`

`

`us 7,892,549 82
`Page 3
`
`WO
`
`WO 2007 145862 A2
`
`12 2007
`
`OTHER PUBLICATIONS
`
`NabholtL. J.M .. Cl al. Brcas1 Cancer Research and Treatment. 64(1 ):
`p. 82. #327, 2000.•
`Nabhoht, J. M. et al .. Europc.'IJI Journal of Cancer. 37(suppl. 6):
`s 190, #695. 2001.•
`Pcrc7 cl al., Seminars in Oncology, 23(5, suppl 11 ): 41 ~5. Ocl.
`1996.•
`van Oostcrom cl al., .. Docciaxel (Taxolere), a review of preclinical
`and cli nical experience. Pa11 II: Clinical experience" Ami-Cancer
`Drugs (Abstracl only) 6(3):356-368 (Jun. 1995).
`Albancll cl al.. ·'Trnstuzumab, a humanized anti-HER2 monoclonal
`antibody, for Ll1e 1rc111mcnt o f breast cance1" Drugs of Today
`35( 12):93 1-946 ( 1999).
`.. Ami noglutethimicle"
`Mal'lindale- The
`Complete
`Dmg
`Referenre Monograp/i.f (website version of product information)
`pp. I~ (2003).
`Argiris and DiGiova.nna,
`.. Synergistic
`interactions between
`trunoxifen and 1 IERCEPTTN TM" Proceedings of the American
`Associa1ion for Canrer Reseaffh (Abstract #4565) 41:718 (Mac.
`2000).
`.. Arimidex (anastrozolc) Table1s" Physicians' Desk Reference
`(website version of producl infonruuion) pp. 1-14 (2003).
`.. Aromasin (cxcmcstane tablets)" Physicians' Desk Reference
`(websi1c version of product infonnation) pp. 1-9 (2003).
`BcnL cl al .. .. Es1rogcn-dcpendenr. trunoxifen-resistant twnorigenic
`growth of MCl'-7 cells transfected with HERl/ncu" Breast CaJ1cer
`Research & Treatmelll 24(2):85-95 ( 1992).
`Brucggcmcicr. R .... Aromatasc. aromatasc inhibitors. and breast can(cid:173)
`cer" American Joumal of Therapeutics 8(5):333-344 (Scp.-Oct.
`1001)
`.. A concerted attack on cancer'' Scrip Magazine 26 I 7(Review Issue
`2000):68-70 (l'cb. 14, 200 I).
`D:lli et al., .. Inhibition of c-crbB-2 oncogene expression by estrogens
`in human breast cancer cells" Oncogene 5(7): I 00 l-1006 (Jul. 1990).
`.. Femara (lclro7ole tablets)" Physicians' Desk Reference (website
`version of product infonna1ion) pp. 1-13 (2003).
`Grcm ct al.. .. A phase II evalua1ion of combination chemotherapy
`plus :11ninoglutc1hi111idc in women wi th metastatic or recurrent breast
`cm·cinoma. An Eastern Cooperative Oncology Group Pilot Study"
`American Joum(I/ of Clinical Oncology 11(5):528-534 (Oct. 1988).
`lfa111il1on :tnd Piccru1 , .. The co ntribution of molecular markers to the
`prediction o r response in 1he trealmcnt of breast cancer: a review of
`the literature o n 1 IER-2, p53 and BCL-2" Annals of Oncology
`l 1(6):647-663 (Jun. 2000).
`Kaufmann cl :11., .. Excmcstanc is superior lo megestrol acetate after
`tarnoxi fen fai lure in postmcnopausal women with advanced breast
`cancer: Rcsullsofa phase Ill randomized double-blind trial" Joumal
`afC/inical Oncology 18(7): 1399-141 l (Apr.2000).
`Konecny ct al. ... New drugs in breast cancer therapy: Current position
`and
`future
`pcrspcc1ives" Gynaekclogisd1-Geburtshiljliche
`R11ndlcha11 (English language abstrac1 only) 37(2):54-61 (Oct.
`1997).
`Kunisuc ct a.I ... Anli-l IER2 antibody enhances the growth inhibitory
`cffec1 of an1i-ocs1rogcn on breast cancer cells expressing both
`oestrogen receptors and I IER2" British Joumal of CaJ1cer 82(1 ):46-
`51 (Jan. 2000).
`Lohrisch and Piccart, .. Breast cancer: new aspects of adjuvant hor(cid:173)
`monal therapy" A11nalsofOncology I l(Suppl. 3): 13-25 (2000).
`Mizukami ct al.. .. EITects of trunoxifcn. mcdroxyprogcsteronc acetate
`and estradiol on 1umor gT0\\1h and oncogene expression in MCF-7
`brea.s1 cancer cell line transplan1ed into nude mice" Amicancer
`Re~earth 11(3): 1333- 1338 (May-Ju n. 199 1).
`Pcgrrun ct al., .. EITcct o f crbB-2 (HER-2/neu) overexpressioo on
`chcmolhcrapcut ic clnig scnsit iv ity in hmnan breast and ovarian can(cid:173)
`cer cells" Pr<X'CC'dillgs of the American Association for Cancer·
`Researth (Abstrnct No. 152)34:26 ( Mar. 1993).
`Picc;u1 and Kaufmann, "Introduction" £11rope(ll1 Joumal o.fC(l11cer
`37(Suppl. l):S l-S2 (Jan. 2001).
`
`Piccart cl al.. .. l IER2: a ·predictive factor' ready to use in the daily
`management of breast cancer patients'?" European Joumal of Cancer
`36(14):1755- 1761 (Sep. 2000).
`Piccart, M .... Closing remarks and treatment guidelines" EuropeaJ1
`Joumal of Cancer 37(Suppl. I ):S30-S33 (Jan. 200 I).
`Pietras et al., .. HF.R-2 lyrosinc kinase pathwaytargetsesrrogen recep(cid:173)
`tor and promotes honnone-indcpcndcnt growth in human breast can(cid:173)
`cer cells" Onrogene I 0( 12):2435-2446 (Jun. 15. 1995).
`Pietras ct al .. .. 1 lcrcgulin pro1no1cs growth o f hwnan breast cancer
`cells with 111:.R-2 (crb B2) rccptors" Proceedings of the AmericaJ1
`Assotiatio11 for Canrer Research (Abstract No. 573) 34:96 (Mar.
`1993).
`Read cl al., .. llormonal modulntion of ll ER-2/neu protooncogcne
`messenger ribonucleic acid <tnd pl 85 protein expression in human
`breast cancer cell lines'' C(ll1rer Reserach 50(13):3947-395 1 (Jul. I,
`1990).
`Warri cl :11., "Estrogen suppression of crbB2 expression is associated
`with increased growth ralc of ZR-75- 1 hlllmtn breast cancer cells in
`vitro and in nude micc" /n1ema1ion(l/Jo11mal ofCa11cer49(4):616-
`623 (Oct. 2 1. 199 1).
`Witters ct al., .. Enha.nccd anli-prolifcralive activity of the combina(cid:173)
`tion of tamoxifen plus llER-2-ncu antibody" Breast Cancer
`ReseaJ·ch & 7i·eat111e11142(1): 1-5 (Jan. l 997).
`"Arc adjuvanl 1 lerccptin trinls using the wrong drugs?" Scrip
`2493:21 (Nov. 26. 1999).
`Arteag.1 cl al., .. pl85"'•·M·! Signaling Enhances Cisplatin-induced
`Cytotoxicity in
`lluman Breast Carcinoma Cells: Association
`Between an Oncogcnic Receptor Tyrosine Kinase and Drug-induced
`DNA Repair" Cancer Research 54( 14):3758-3765 (Jul. 15. 1994).
`Bacus ct al .. .. Differentiation ofCulrured lluman Breast Cancer Cells
`(AIJ-565 and MCl--7) Associated With Loss of Cell Surface HER-2
`neu Antigen" Molecular Carcinogenesis 3(6):350-362 (1990).
`Bacus ct al .. ·-rumor-inhibi1ory Monoclonal Antibodies to the HER-
`2 Neu Receptor Induce U11lcrcnt1auon of Human Breast Cancer
`Cells" Ca11('(!1' Rese(lrth 52(9):2580-2589 (May I. 1992).
`Basclga and Mendelsohn, ··Receptor Blockade With Monoclonal
`Antibodies As Anti-Cancer Therapy" Plwn11ac. TheJ: 64:127- 154
`( 1994) .
`Dasclg.1 ct :11., .. Anti 1 IER2 llurnanizcd Monoclonal Antibody(MAb)
`Alone and in Combination with Chemotherapy Against Human
`Breast Carcinoma Xcnogrnfls" Proceedings of ASC0-13th Annual
`Mee1ing (Abslracl 1153), Dallas, TX 13:63 (Mar. 1994).
`13aselga cl al., "Anlitumor activity ofpaclila.-<cl in combination with
`anti-growth foctor recept or monoclonal antibodies in breast cancer
`xenogralls" Proceeding.1· of 1he American Association for Cancer
`Researd1 (Abslracl No. 2262) 35:380 (Mar. 1994).
`Basclga ct al. ... Antilumorcffects o fdoxorubic in in combination with
`anli-cpidermal growth factor receptor monoclonal antibodies" Jour(cid:173)
`nal of the Nalional Cancer Inst it/lie 85( 16): 1327-1333 (Aug. 18,
`1993).
`13aselga cl al. . .. 1 IER2 Ovcrcxprcssion and Paclitaxel Sensitivity in
`Breast Cancer: Therapeutic Implications" 0 11cology (Supplement
`No. 2) 11(3):43~8 (Mar. 1997).
`Basclga ct al. ... Monoclonal Antibodies Directed Against Growth
`Fac1or Receptors Enhance the Efficacy of Chemotherapeutic
`Agents." Annals of011colog,•(abstract 110 10) 5(Suppl. 5) ( 1994).
`Basclga cl al. ... Phnsc II Sn1dy of Weekly Intravenous Recombinant
`llurnani/ed Anli·pl8511r.it2 Monoclonal Antibody in Patients With
`I !ER2 ncu-Ovcrcxprcssing Metastatic Breast Cancer'' J. Cli11.
`011rol. 14(3):737-744 (Mac. 1996).
`Baselga el al .... Rccombinan1 Humanized Anti-HER2 Antjbody
`(llcrccptin) Enchances the Antitumor Activity of Paclita'<el and
`Doxorubicin against 1 IER2 ncu Ovcrcxpcssing Human Breast Can(cid:173)
`cer Xenografts·• Cancer Research 58:2825-2831 (Jul. 1998).
`Bunn cl al., .. llER2, ncu expression and effects of Herceptin alone
`and in combirmtion with cytotoxic agents in lung cancer" Proceed(cid:173)
`ings of the Amffiran Assotialionfol' Cancer Research (Abstract No.
`4 57 1)4 1:7 19(Mar. 2000).
`Burris et al., .. Pha.sc II trial of doccta-<el and Herceptin(R) as Firsl- or
`second-li ne chemothcmpy for women with metastatic breast cancer
`whose t111nours ovcrcxprcss ll ER2" European Joumal of Cancer
`(Abstract No. 1293)35(4):$322 (Sep. 1999).
`
`3 of 24
`
`Celltrion, Inc., Exhibit 1001
`
`

`

`US 7,892,549 B2
`Page4
`
`Carmichael et al., "Advanced breast cancer: a phase n trial with
`gemcitabine" Joumal of Clinical Oncology 13(11 ):273 1-2736 (Nov.
`1995).
`Cannichael et al., "Advanced breast cancer: investigational role of
`gemcitabine" European Joumal of Cancer 33(Suppl. l):S27-S30
`(Jan. 1997).
`Carter ct al.. "Humanization of an Anti-p l85HER~ /\.ntibody For
`liuman Cancer Therapy" Proc. Natl. A cad. Sci. USA 89:4285-4289
`(May 1992).
`Clemons ct al., "Review of recent trials of chemotherapy for
`advanced Breast cancer: studies excluding taxanes" European Jour(cid:173)
`nal of Cancer 33(13):2 171-2182 (Nov. 1997).
`D'Souza and Taylor-Papadimitriou .. "Overexpression of ERBB2 in
`Human Mrunmary Epithelial Cells Signals Inhibitio n of Transcrip(cid:173)
`tion of the E-CadheJ'in Gene." Proc. Natl. Acad. Sci. USA
`91(15):7202-7206 (Jul. 19, 1994).
`Davidson. N .. ''Single-agent paclitaxel ai first relapse followin gadju(cid:173)
`vant chemotherapy for breast cancer" Seminars in Oncology 22(6
`Suppl 14):2-6 (Dec. 1995).
`De Saoteset a l., "RadiolabeledAnlibodyTargei ing of the HER-2/oeu
`Oncoprotcin" Cancer Research 52: 19 16-1923 (1992).
`Di Fiore et al., "erbB-2 ls A Potent Oncogene \\'hen Overexprcssed
`In NIH/3T3 Cells." Science 237(48 11): 178- 182 (Jul. 10, 1987).
`Dl'cbin cl al.. "Down-Modulation of an Oncogene Protein Product
`and Reversion of the Transformed Phenotype by Monoclonal Anti(cid:173)
`bodies" Ceff 41 (3):695-706 (Jul. 1985).
`Drebin et al., "Inhibition ofTlunor Growth By a Monoclonal Anti(cid:173)
`body Reactive With an Oncogene-Encoded Tumor Anti gen" Proc.
`Natl. A cad. Sci. 83:9129-9 133 ( 1986).
`Drcbin et al., "Monoclonal Antibodies Reactive With Distinct
`Domains of the ncu Oncogene-Encoded pl85 Molecule E.xert Syn(cid:173)
`ergistic Anti-Tumor Elfects In Vivo" Oncogene 2:273-277 (1988).
`Drcbin et al.. "Monoclonal Antibodies Specific fol' the ncu Oncogene
`Product Direclly Mediate Anti-tumor E1Tects ln Vivo" Oncogene
`2(4):387-394 ( 1988).
`Fendly, B.M. et al., "Characterization of Murine Monoclonal Anti(cid:173)
`bodies Reactive to Either the Human Epidermal Growth Factor
`Receptor or HER2/neu Gene Product" Cancer Research 50: 1550-
`1558 (Mar. 1. 1990).
`Flciss, JLStatistical Methods for Ratesa11d Proportio11s, 2nd edition.
`New York, l\'Y:Wiley pp. 13-17 ( 1981).
`Fornier el al.. ··Trastuzurnab in combination with chemotherapy for
`lhe lrealmentofmetastatic breast cancer" Seminars in Oncology27(6
`Suppl 11):38-45 (Dec. 2000).
`Gatzemeier et al., "A randomised phase 11 study of gemcitabinel
`cisplatin alone and with Herceptin in patients with HER2-positive
`non-small cell lung cancer (NSCLC)" (Poster to be presented at the
`200 l ECCO meeting).
`Gemz.-u· (gemcitabine HCL), "Product lnfonnation- PDR" (2000).
`Green et al., "Preclinical Evaluation of WR-151327: An Orally
`Active Chemotherapy Protector" Cancer Research 54(3):738-741
`(Feb. I, 1994).
`Guy et al., "Expression of the neu Protooncogene in the Mammary
`Epithelitun of Transgenic Mice Induces Metastatic Disease." Proc.
`Natl. A cad. Sci. USA 89(22): 10578-10582 (Nov. 15. 1992).
`Hancock et al., "A Monoclonal Antibody Against the c-e rbB-2 Pro(cid:173)
`tein Enhances the Cytotoxicity of cis-Diamminedichloroplatinum
`Against Human Brcasl and Ovarian Tumor Cell Lines" Cancer
`Research5l :4575-4580(Sep. I, 199 1).
`Hansen, H ., "Gerncitabine-a review" Annals of Oncology (Abslraci
`#058 from the 9th NCl-EORTC Symposiwn on New Dnigs in Cancer
`Therapy held in Amsterdrun on Mar. 12-15. 1996) 7(Suppl. 1):29
`(1996).
`Harwenh el al .. "Monoclonal Antibodies Against the Extracellular
`Domain of the erbB-2 Receptor Function as Prutia.I Ligand Agon ists"
`Journal of Biological Che111ist1y 267(21): 15160- 15167 (Jul. 25,
`1992).
`" Herceptin (Trastuzumab)" Product Information (2000).
`Hudziak el a l., ''Increased Expression of the Putative Growth Factor
`Receptor pl85H£Rl Causes Transformation and Tumorigenesis of
`Nl113T3 Cells" Proc. Natl. Acad. Sci. USA 84(20):7159-7163 (Oct.
`1987).
`
`Hudziak et al., "p I 85HER2 Monoclonal Antibody Has Antipro lifera(cid:173)
`tive Effects In Vitro and Sensitizes Human Breast Tumor Cells to
`Tumor Necrosis Factor" Molecular & Cellular Biology 9(3): 1165-
`1172 (Mar. 1989).
`Hynes and Stern., "The BiologyoferbB-2/neu/HER-2 and lls Role in
`Cancer." Biochimica et Biophysica Acta 1198(2-3): 165-184 (Dec.
`30, 1994).
`Ilgcn ct al., "Characterization of anti-HER!2 antibodies which inhibit
`!he growth of breast tumor cells in vitro" Proceedings of the Ameri(cid:173)
`cm1 Association for Cancer Research (abstract #3209) 37:470 (Mar.
`1996).
`Kasprzyk ei al., "Therapy of an Animal Model of lltunan Gastric
`Cancer Using a Combination of Anti-erbB-2 Monoclonal Antibod(cid:173)
`ies" Cancer Research 52(10):277 1-2776 (May 15, 1992).
`Konecny ct al., "Therapeutic advantage of chemotherapy drugs in
`combination with Herccptin against htunan breast cancer cells with
`HER-2/l\IEU overexpression" Breast Cancer Res Treat (Abstract No.
`467) 57:114 ( 1999).
`Kotts el al., "Differential Growth Inhibition of Human Carcinoma
`Cells Exposed to Monoclonal Antibodies Directed against the
`Extracellular Domain of the HER21ERBB2 Protooncogene" In Vitro
`(Abstract # 176) 26(3):59A ( 1990).
`Kumar et al., "Regulation of Phosphorylation of the c-erbB-2/HER2
`Gene Product by a Monoclonal Antibody and Senun Growth Fac(cid:173)
`tor(s) in Human Mrurnmuy Carcinoma Cells" Molecular & Cellular
`Biology 11 (2):979-986 (Feb. 199 J ).
`Lewis ct al., ··oiJTerential Responses of Human Tumor Cell Lines to
`Anti-p I 85HER; Monoclonal Antibodies." Cancer
`!111111111101.
`Immunothet: 37:255-263 ( 1993).
`Lewis et al .. "Growth Regulation of Human Breast and Ovarian
`Ttunor Cells by Heregulin: Evidence for the Requirement of ErbB2
`as a Critical Component in Mediating Heregulin Responsiveness"
`Cancer Research 56:1457-1465 (Mar. 15, 1996).
`Llomba.rt el a.I. , "Biweekly gemcita.bine and paclitaxe l in advanced
`breast cancer. Phase Il lrial and predictive value of HER2 extracel(cid:173)
`lular domain (ECO)" European Journal of Cancer (Abstract No.
`390) 36(Suppl 5):S 12 1-S l 22 (Sep. 2000).
`Maier et al .. "RcquiJ'emcnts for the Internalization of a Murine
`Monoclonal Antibody Direetedagainst the HER-2/neu Gene Product
`c-erbB-2" Cancer Research 51( 19): 536 1-5369 (Oct. l , 199 1 ).
`Masui et al., "Growth Inhibition of Human Tumor Cells in Athymic
`Mice by Anti-Epidermal Growth Factor Receptor Monoclonal Anti(cid:173)
`bodies" Cancer Research 44(3): 1002-1007 (Mar. 1984).
`Masnko et al., "A murine Monoclonal Antibody That Recognizes an
`E.xtracellular Domai.n of the Human c -erbB-2 Protooncogene Prod(cid:173)
`uct" Jpn J. Cm1cer Res. 80:10-14 (Jan. 1989).
`McCann et al.. "c-erbB-2 Oncoprotein E,xpression in Primary Human
`Twnors" Cancer 65(1):88-92 (Jan. l. 1990).
`McKenzie et al., ''Generation and Characterization of Monoclonal
`Antibodies SpeciJic for lhe Human neu Oncogene Product, p185"
`Oncogene 4 :543-548 ( 1989).
`Mendelsohn et al .. "Receptor Blockade and Chemotherapy: A New
`Approach to Combin;1tion Cancer therapy. " Annals of Oncology
`(abstract #040) 7(Suppl. I ):22 ( 1996).
`Miller et al., "Gemcitabine, pa.clitaxel, and trastuzumab in metastatic
`breast cancer'' Oncology 15(2 Supp 3):38-40 (Feb. 200 I).
`Miller el al.. "Phase II study of gemcitabine. paclitaxel and
`trastuzumab in metastatic breast cancer; a Hoosier Oncology Group
`trial" (Abstract #437. Presented at the 2002 SABCS meeting.)
`(2002).
`Mosconi et al .. '·Combination therapy with gcmcitabine in non-small
`cell lung cancer" European Joumal of Cancer 33(Suppl. I ):S 14-S 17
`(Jan. 1997).
`Myers et al .. "Biological Effects of Monoclonal /\.ntireceptor Anti(cid:173)
`bodies Reactive with neu Oncogene Product, p I 85neu" Methods in
`Enzymology 198:277-290 ( 199 1).
`Nagoumcy et al., "Trast-uzumab (Hcrceptin) enhancement of
`cytotoxic drug activity in bw11an tumor primary cultures" Breast
`Cancer Res 'li'eat (Abstract No. 475) 57:116 (1999).
`Nelson and Fry. ''Inhibition of ERBB family receptors by C 1- J 033
`enhances the cyt.otoxici ty o f gemcitabi ne via modu lation of AKT and
`map kinascs" Proceedings of the American Association for Cancer
`Researclt(AbslractNo. 1533)4 1:241(Mar.2000).
`
`4 of 24
`
`Celltrion, Inc., Exhibit 1001
`
`

`

`US 7,892,549 B2
`Page 5
`
`Norton, L .. "Evolving Concepts in the Systemic Drug Therapy of
`Breast Cancer." Seminars in Oncology 24( 4 Suppl I O):S I 0-3-S 10-10
`(Aug. 1997).
`Pegram et al., "lnhibito1y effects of combinations of HER-2/neu
`antibody and chemolherapeur.ic agents used for treatment of human
`breast cancers" Oncogene 18:224 1-2251 (1999).
`Pietras ct al.. "Antibody to HER-2/neu Receptor Blocks DNA Repair
`After Cisplatin in Human Breast and Ovarian Cancer Cells"
`Oncogene 9: 1829-1838 ( 1994).
`Raefsky et a l., " Phase II Trial ofDocetaxcl and Hcrceptio as First-or
`Second-Line Chemotherapy for Women with Metastatic Breast Can(cid:173)
`cer Whose Tumors Overexpress HER2" Proceedings of ASCO
`(Absrracr #523) J8:137a (1999).
`Ravdin and Chamness, '·Tue c -erbB-2 prolo-oocogene as a prognos(cid:173)
`tic and predictive marker in breast cancer: a paradigm for the devel(cid:173)
`opment of other macromolecular markers- a review" Gene
`159( 1): 19-27 (Ju.n. 14, 1995).
`Rodeck et al., "Interactions between growth factor receptors and
`corresponding monoclonal antibodies in human tumors" J. Cellular
`Biochem. 35(4):3 15-320 ( 1987).
`Safran er al.. "Herceptin and gemci tabine for metastatic pancreatic
`cancers that overexpress HER-2/neu" Proc. Am. Soc. Cli11. 011col.
`(Abstract No. 517) 20: 130A (200 I).
`Sarup et al., "Characterization of an Anti-P l85H£R2 Monoclonal
`Antibody that Stimulates Receptor Function and Inhibits Tumor Cell
`Growth" Growth Regulation 1:72-82 ( 199 1).
`Schlom, J., "Monoclonal Anti bodies: They're More and Less Than
`You Think'' Molecular Fou11dario11s of Oncology. Broder. S. ed.,
`Baltimore. MD:Williams & Wilkins, Chapter 6, pp. 95-134 (1991).
`Scott et al., "pl851·LER2 Signal Transduction in Breast Cancer Cells"
`.Journal of Biological Chemis11y 266(22): 14300-14305 (Aug. 5,
`1991).
`Seidman cl al., "Memorial Sloan-Kettering Cancer Center experi(cid:173)
`ence with pacljtaxel in the treatment of breast cancer" Seminnrs in
`Oncology 22(5 Suppl 12): 108-1 16 (Oct. 1995).
`Sei fen et al., .. Dexrazoxane in the prevention or doxonibicin-i nduced
`cardiotoxicity" Annals of Pharmacorherapy 28(9): 1063- L072 (Sep.
`1994).
`Shawver er al., .. Ligand-Li ke EITects Induced by Anli-c-erbB-2 Anti(cid:173)
`bodies Do Not Correlate wi th and Are Nol Required for Growth
`inhibition of Human Carcinoma Cells" Cancer Research
`54(5): 1367-1373 (Mar. 1, 1994).
`Shepard el al .. "Monoclonal Antibody Therapy of Human Cancer:
`Taking the HER2 Protooncogene to lhe Clinic" J. Cli11. Jmmunol.
`11(3): 117-127 (1991).
`Singal and lliskovic, "Doxonibicin-induced cru·diomyopathy" New
`England J. of Medicine 339(13):900-905 (Sep. 24, 1998).
`therapy with probucol prevents
`.. Combination
`Singal et al..
`adrirunycin-induced cardiomyopathy" Joumal ofMoleculnr & Cel(cid:173)
`lular Cardiology 27(4): 1055- 1063 (Apr. 1995).
`Slrunon et al., " Human Breast Cancer: Correlation of Re lapse and
`Survival wilh Amplification of the HER-2/neu Oncogene" Science
`235: 177- 182 (Jan. 9, 1987).
`Slamon el al. ... Stu dies oflhe HER-2/neu Proto-Oncogene in Human
`Breast and Ovru·ian Cancer" Science 244:707-712 (May 12. 1989).
`Sliwkowski ct al., .. A htunan izcd monoclonal antibody for the treat(cid:173)
`ment of HER2 overexpressing breast cancer" Proceedings of rhe
`American Association for Cancer Research (abstracl only) 37:625-
`626 (Mar. 1996).
`Sliwkowski et al., .. Coexpression of erbB2 and erbB3 Proteins
`Reconstitutes a High Affinity Receptor for Heregulin" .Joumal of
`Biological Che111i.~t1y269(20): 14661 -1 4665 (May 20, 1994).
`Stancovski et al., "Mechanistic Aspects of the Opposing Effects of
`Monoclonal Antibodies to the ERBB2 Receptor on Tumor Growth"
`Proc. Nari. Acad. Sci. USA 88(19):8691 -8695 (Oct. I, 1991).
`Tagliabue et al., "Selection of Monoclonal Antibodies Which Induce
`Internalization and Phosphorylation ofpl 85n£Ri and Growth Inhi(cid:173)
`bition of Cells With J-IER211'.TEU Gene Amplification" !nremarional
`.Joumal of Cancer 47(6):933-937 (Apr. l. 1991).
`Tsai el al., .. Cytotoxic effects o f gemcitabine-conlaining regimens
`agai nst human non-small cell lung cancer cell lines w hich express
`different levels of pl 85""'M Cancer Research 56( 4):794-80 l (Feb. 15.
`1996).
`
`van Moorsel et al., ''Combin ation chemotherapy studies with
`gemcitabine" Seminars in Oncology 24(2 Suppl. 7):S7-17-S7-23
`(Apr. 1997).
`Vitetta and Uhr. "Monoclonal Antibodies as Agonists: An Expanded
`Ro le
`fo r The ir Use in Cancer Therapy'' Cancer Research
`54(20):5301-5309 (Oct. 15, 1994).
`Xu etal., "Antibody-Induced Growth Inhibition is Mediated Through
`l.nununochcmically ru1d Functionally Distinct Epitopcs on the
`Extracellular Domai n of the c-erbB-2 (HER-2/neu) Gene Product
`p 185" !111emarional.Joumal of Cancer 53(3):40 l-408 (Feb. I. 1993).
`Zhang el al., "Shared antigeni c epitopes and pathobiological ti.Jnc(cid:173)
`tions of anti-p l 851'"r21
`""' monoclonal anlibodies" E.\perimemal and
`Molecular Parhology 67: 15-25 ( 1999).
`Zinner et al., .. Cispla1ion and gemcitabine combined with Herceplin
`in patients (Pts) with HER2 overexpressing, tmtreated, advanced,
`non-small-cell lungcancer(NSCLC);a phase 11 trial" Proc. Am. Clin.
`011col. Abstract No. 1307) 20:328A (200 l ).
`Buzdar et al., "Anastrozole, a potent and selective aromatase inhibi(cid:173)
`tor. versus megestrol acetate in postmenopausal women with
`advanced breast cancer: results o f overview analysis o flwo phase m
`trials" .Joumal of Clinical Oncology 14(7):2000-2011(Jul.1996).
`Buzdar et al., "Fadrozole HCL (CGS-16949A) versus mcgestrol
`acetate treatment of postmenopausal pal ients with meraslatic breast
`carcinoma: resu.lts of two randomized double blind controlled
`multi.institutional trials" Cancer 77(12):2503-2513 (Jun. 15. 1996).
`Dickman, S., "Antibodies stage a comeback in cancer treatment"
`Science 280(5367): I 196-l 197 (May 22, 1998).
`Grant el al.. "Compariso n of antiangiogenic activities using
`paclitaxel (taxol) and docetaxel (taxotere)" lntemarional Joumaf of
`Cancer 104(1):121-129 (Mar. JO. 2003) .
`Kaye ct al., "Phase 11 trials of doceta'<cl (Taxotcrc) in advanced
`ovarian cancer- an updared overview" European .Joumal of Cancer
`33(13):2 167-2170 (Nov. 1997).
`Klijn et al.. "Clinical breasr cancer. new developments in selection
`and endocrine treatment of patients" Journal o/Sreroid Biochemis11y
`&Molecular Biology43(1-3):2 1 l-22 1 (Sep. 1992).
`Merlin et al., .. In vitro co mparat.i ve evaluation of trastuzumab
`(Herceptin)combined wilh paclita'<el (Taxol) ordoceta.'<el (Taxolere)
`in HERZ-expressing human breast cancer cell lines" Annals of
`Oncology 13( 11): I743- 1748 (Nov. 2002).
`Nallani et al .. "Differences in the in duction of cyrocbrome P4 50 3A4
`by raxane anticancer dnigs, docetaxel and paclitaxel, assessed
`employing primary human hepatocytes" Cancer Chemorherapy &
`Pharmacology 54:219-229 (Sep. 2004).
`Santen and Harvey, "Use of ru·omatase inhibitors in breast carci(cid:173)
`noma" Endocrine-Reltued Cancer 6( 1 ):75-92 (Mar. 1999).
`Untch et al.. "Comparison of paclita.xel and doceta'<el (Ta.'<otere) in
`gynecologic and breast cancer cell lines wiih the ATP-cell viability
`assay" Ami-Cancer Dmgs 5(1):24-30 (Feb. J994).
`Agus et al., "Clinical Activity in a Phase I Trial ofHER-2-Targeled
`rhuMAb 2C4 (pertuzumab) in Patients with Advanced Solid Malig(cid:173)
`nancies (AST)" Proceedings ofrhe American Associario11/or Cancer
`Research (Abstract No. 77 I) 22: 192 (2003).
`Agus et al., "Clinical Activity in a Phase I Trial of HERZ-Targeted
`rhuMAb 2C4 (pertuzuma